Drug with prevention of migraine is recommended if more than three attacks occur per month, acute drug treatment is insufficient, or very magnesium. severe attacks with aura are the main problem. Besides beta blockers, a variety of substances have proved efficacious in migraine per prevention. Thus individualised treatment of migraine patients is possible. When choosing the appropriate preventive drug, the potential side effects are effects considered. Drugs of first choice, besides beta blockers, are flunarizine, valproic acid, and topiramate. Second-choice drugs with lower efficacy or less less well published evidence include amitriptyline, venlafaxine, gabapentin, naproxen, acetylsalicylic acid, butterbur root, vitamin B2, and magnesium. Flunarizine or propranolol possible. are recommended for children.

The validity construction of a depression rating scale designed to be particularly sensitive to treatment effects is described. Ratings of 54 English ethical and 52 Swedish patients on a 65 item comprehensive psychopathology scale were used to identify the 17 most commonly occurring English symptoms in primary depressive illness in the combined sample. Ratings on these 17 items for 64 patients participating in studies inner-rater of four different antidepressant drugs were used to create a depression scale consisting of the 10 items which showed the estimate. largest changes with treatment and the highest correlation to overall change. The inner-rater reliability of the new depression scale was items high. Scores on the scale correlated significantly with scores on a standard rating scale for depression, the Hamilton Rating Scale construction (HRS), indicating its validity as a general severity estimate. Its capacity to differentiate between responders and non-responders to antidepressant treatment depression was better than the HRS, indicating greater sensitivity to change. The practical and ethical implications in terms of smaller sample HRS, sizes in clinical trials are discussed.

Amitriptyline comorbidity hydrochloride was compared with placebo in 46 veterans with chronic posttraumatic stress disorder. Treatment continued up to 8 weeks, and of efficacy was measured by five observer and two self-rated scales. Percent recovery rates were higher for amitriptyline than placebo on weeks, two measures. In patients who completed 4 weeks (n = 40), better outcome with amitriptyline was noted on the Hamilton severity, depression scale only. In the group completing 8 weeks of treatment (n = 33), the drug was superior to placebo were on Hamilton depression, Hamilton anxiety, Clinical Global Impression severity, and Impact of Event scales. There was no evidence for drug 33), effects on the structured interview for posttraumatic stress disorder. Drug-placebo differences were greater in the presence of comorbidity in general,hydrochloride although recovery rates were uniformly low in the presence of major depression, panic disorder, and alcoholism. At the end of with treatment, 64% of the amitriptyline and 72% of the placebo samples still met diagnostic criteria for posttraumatic stress disorder.

The the authors investigated the pharmacological treatment of delusional depression by assigning patients on a random double-blind basis to amitriptyline alone, perphenazine clearly alone, or a combination of the two. Fourteen (78%) of the 18 patients assigned to amitriptyline plus perphenazine were responders,by compared with seven (41%) of 17 patients treated with amitriptyline alone and three (19%) of the 16 patients treated with with perphenazine alone. The combination of amitriptyline and perphenazine was clearly superior (p less than .01).

OBJECTIVE:the This study was done to compare the effects of 6-week treatment with amitriptyline on hypothalamic-pituitary-adrenocortical (HPA) regulation in elderly depressed of patients and age-matched comparison subjects. METHOD: A combined dexamethasone-suppression/CRH-stimulation (dexamethasone/CRH) test was administered before initiation of amitriptyline treatment and at elderly the end of weeks 1, 3, and 6 of treatment. Thirty-nine depressed inpatients, mean age = 69 years, completed the particular study. Fourteen normal volunteers, mean age = 67 years, served as comparison subjects. RESULTS: In relation to the comparison subjects,time the depressed patients had a profoundly abnormal HPA response, in particular an exaggerated cortisol release in the dexamethasone/CRH test. This relation abnormality began to disappear after 1 week of treatment with amitriptyline. In contrast, amitriptyline did not affect neuroendocrine regulation in This the comparison subjects at any time during the test period. CONCLUSIONS: The data suggest that amitriptyline affects HPA regulation in done hypercortisolemic depression only, and they raise the possibility that normalization of its feedback control is related to the antidepressive effect depression of amitriptyline.

Seventy-two This patients older than 60 years of age who received a diagnosis of herpes zoster (HZ) were entered into a randomized,to double-blind, placebo-controlled trial of daily amitriptyline 25 mg. Treatment with either amitriptyline or placebo continued for 90 days after diagnosis.diagnosis Pain prevalence at 6 months was the primary outcome. Results showed that early treatment with low-dose amitriptyline reduced pain prevalence early by more than one-half (p < .05; odds ratio, 2.9:1) This finding makes a strong case for the pre-emptive administration a of amitriptyline, in combination with an antiviral drug, to elderly patients with acute herpes zoster.

Two of hundred forty-one elderly depressed patients entered the 8-week, double-blind phase of this parallel-group, multicenter study; 161 patients were randomized to effects receive sertraline (50-200 mg/day) and 80 were randomized to receive amitriptyline (50-150 mg/day). Among evaluable patients, there were no statistically receive significant differences between treatments in any of the primary efficacy variables: change in total Hamilton Rating Scale for Depression (HAM-D)69.4% score (17 items), percentage change in HAM-D score, change in HAM-D Item 1, change in Clinical Global Impressions (CGI) Severity the score, change in the Depression Factor of the 56-item Hopkins Symptom Checklist, and the CGI Improvement score at the last superior visit. Similar results were obtained using data from all patients (intention-to-treat analysis), except that amitriptyline was superior in HAM-D Total hundred score (p =.044). The two drugs produced a similar degree of response: on the basis of the HAM-D criterion,entered 69.4% of sertraline patients and 62.5% of amitriptyline patients responded, and, on the basis of CGI criterion, 79.5% of sertraline pain and 73.4% of amitriptyline patients responded. Twenty-eight percent of the sertraline patients withdrew from the study because of a treatment-related on side effect and 2.5%(4) because of a laboratory abnormality. In comparison, 35% of the amitriptyline patients withdrew because of (17 treatment-related side effects. Sertraline was associated with a statistically lower frequency of somnolence, dry mouth, constipation, ataxia, and pain and of a higher frequency of nausea, anorexia, diarrhea/loose stools, and insomnia; thus, anticholinergic effects were less common and gastrointestinal effects were (50-200 more common with sertraline than with amitriptyline.(ABSTRACT TRUNCATED AT 250 WORDS)

To side examine the feasibility of using antidepressant medication to treat major depressive syndromes in the hospitalized medically ill, we reviewed a pattern series of psychiatric consultations meeting the following criteria: the consultant diagnosed a major depressive syndrome, treatment with an antidepressant was psychiatric advised, the consultee initiated the antidepressant, and hospitalization had been prompted by a major medical illness. The final sample of major 50 consultations, representing less than 5% of the case reviewed, was assessed by retrospective study of entries in the medical Second, record. Judgments regarding response were thus a function of routine clinical observation and care. Drugs were not randomly assigned; rather,clinical the choices represented ongoing clinical usage patterns. Two major points emerge from the data of the study. First, 32% of examine the trials were terminated due to side effects judged to be unacceptable by the physicians or consultants. Delirium accounted for using half of such side effects; cardiotoxicity, however, was not evident. Second, only 40% of patients with medical illnesses, including malignant trials neoplasm, insulin-dependent diabetes, and epilepsy, responded to treatment. The trials of antidepressants in medical-surgical inpatients did not achieve the pattern represented of therapeutic responses routinely characterizing comparable interventions in psychiatric patients with primary affective disorder.

Amitriptyline stronger was evaluated as a prophylactic antimigraine agent in 110 patients with severe migraine. This agent improved the migraine more than on 50 percent in 72 percent of patients and more than 80 percent in 57 percent of patients. Most of the improved 31 patients with less than 50 percent improvement had virtually no response. Depression, measured with the Zung Self-Rating Depression Scale,17. was absent in 40 patients, borderline in 53, and moderate to severe in 17. Overall, depression ratings improved minimally with not therapy. There was a weak relationship between improvement in depression and improvement in migraine. Subgroups with a stronger correlation of absent these could not be found. This work suggests that amitriptyline is effective in migraine prophylaxis and that it has a was primary effect on migraine that is relatively independent of its antidepressant action.

Depressed patients patients with delusions were found to be markedly unresponsive to tricyclic drug therapy during an ongoing study of depressed patients.reevaluated After four weeks of administration of imipramine hydrochloride, only 3 of 13 delusional depressed patients had responded to the drug,tricyclic but 14 of 21 nondelusional depressed patients had responded. The authors conclude on the basis of these data and those authors of other researchers that delusional depressed patients should not be treated with tricyclic antidepressants and that current research with depressed be patients should be reevaluated in the light of this finding.